A Phase 1/2, First-in-Human, Multicenter, Open-Label Study of SQZ-eAPC-HPV as Monotherapy and in Combination with Immune Checkpoint Inhibitor(s) in Patients with HPV16+ Recurrent, Locally Advanced, or Metastatic Solid Tumors
Histologically confirmed incurable or metastatic solid tumor (including but not limited to cervical and head and neck tumors) that are HPV16+ as determined by histological or HPV16 molecular analysis.
University of Colorado Hospital
Antonio Jimeno, MD, PhD
Protocol Number: 22-0228
More information available at ClinicalTrials.gov: NCT05357898
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers